Report cover image

Castrate-resistant Prostate Cancer Market Growth, Size, Trends Analysis - By Therapy - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Publisher SPER Market Research Pvt. Ltd.
Published Feb 06, 2025
Length 239 Pages
SKU # SPER19656786

Description

Castrate-resistant Prostate Cancer Market Introduction and Overview

According to SPER market research, ‘Global Castrate-resistant Prostate Cancer Market Size- By Therapy – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Castrate-resistant Prostate Cancer Market is predicted to reach 30.78 billion by 2034 with a CAGR of 8.91%.

Castration-resistant prostate cancer (CRPC) is a type of advanced prostate cancer that is resistant to conventional hormone therapy. In CRPC, the cancer grows despite low testosterone levels in the body, which are usually the result of surgical or medicinal castration.

Restraints:The limited effectiveness of treatments and their high costs are hindering market growth for CRPC. Many treatments are too expensive for patients without insurance, making them hard to access. The severe side effects from treatments like chemotherapy and immunotherapy can negatively affect patients’ quality of life, making it hard to stick to their plans. Although there are various treatments for CRPC, not all patients will respond to them. Some may develop resistance, complicating disease management and prolonging survival challenges.

Scope of the Report:

Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Therapy.

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered

Sanofi, Johnson & Johnson Services, Inc, Pfizer, Inc, Astellas Pharma, Inc, Bayer AG.

Castrate-resistant Prostate Cancer Market Segmentation:

By Therapy:Based on the Therapy, Global Castrate-resistant Prostate Cancer Market is segmented as; Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy.

By Region:This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

239 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Castrate-resistant Prostate Cancer Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Castrate-resistant Prostate Cancer Market
7. Global Castrate-resistant Prostate Cancer Market, By Therapy (USD Million) 2021-2034
7.1. Chemotherapy
7.2. Hormonal Therapy
7.3. Immunotherapy
7.4. Radiotherapy
8. Global Castrate-resistant Prostate Cancer Market, (USD Million) 2021-2034
8.1. Global Castrate-resistant Prostate Cancer Market Size and Market Share
9. Global Castrate-resistant Prostate Cancer Market, By Region, (USD Million) 2021-2034
9.1. Asia-Pacific
9.1.1. Australia
9.1.2. China
9.1.3. India
9.1.4. Japan
9.1.5. South Korea
9.1.6. Rest of Asia-Pacific
9.2. Europe
9.2.1. France
9.2.2. Germany
9.2.3. Italy
9.2.4. Spain
9.2.5. United Kingdom
9.2.6. Rest of Europe
9.3. Middle East and Africa
9.3.1. Kingdom of Saudi Arabia
9.3.2. United Arab Emirates
9.3.3. Qatar
9.3.4. South Africa
9.3.5. Egypt
9.3.6. Morocco
9.3.7. Nigeria
9.3.8. Rest of Middle-East and Africa
9.4. North America
9.4.1. Canada
9.4.2. Mexico
9.4.3. United States
9.5. Latin America
9.5.1. Argentina
9.5.2. Brazil
9.5.3. Rest of Latin America
10. Company Profile
10.1. Sanofi
10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary
10.1.4. Recent developments
10.2. Johnson & Johnson Services, Inc
10.2.1. Company details
10.2.2. Financial outlook
10.2.3. Product summary
10.2.4. Recent developments
10.3. Pfizer, Inc
10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments
10.4. Astellas Pharma, Inc
10.4.1. Company details
10.4.2. Financial outlook
10.4.3. Product summary
10.4.4. Recent developments
10.5. Bayer AG
10.5.1. Company details
10.5.2. Financial outlook
10.5.3. Product summary
10.5.4. Recent developments
10.6. Others
11. Conclusion
12. List of Abbreviations
13. Reference Links

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us